Natalya Davies's questions to Ironwood Pharmaceuticals Inc (IRWD) leadership • Q3 2024
Question
Natalya Davies inquired about expectations for a potential increase in SG&A expenses related to prelaunch costs for apraglutide and the outlook for R&D spending in 2025.
Answer
Sravan Emany, COO and CFO, stated that specific 2025 guidance would be provided next year. However, he emphasized that the company plans to leverage its significant existing commercial infrastructure for the apraglutide launch, implying potential cost efficiencies rather than a major jump in spending.